Description
Cefpodoxime and Clavulanic Acid Tablets – The tablets are grouped as antibiotics. This tablet is associated with helping in the treatment of bacterial attacks causing tonsil and ear infections associated with otitis media. Additionally, gonorrhea, a sexually transmitted infection, a respiratory tract infection that causes pneumonia, and a severe sinus infection are all reversed.
These are the tablets that are available for franchise business PAN India by FC remedies, supplied under the brand name Stage-CV. They are highly in demand due to their benefits in treating urinary tract infections, anorectal infections in women, and sometimes various skin bacterial infections.
Cefpodoxime 200 mg and Clavulanic Acid 125 Mg Tablets is a combination of two antibiotics known as Cefpodoxime, which is a cephalosporin antibiotic, and Clavulanic Acid, which is known as the beta-lactamase inhibitor.
Cefpodoxime is responsible for damaging the outer covering of the bacterial cells, which is very important for their survival. Since the outer layer of bacteria is destroyed by the salt, their survival becomes nearly impossible, leading to a reduction in their DNA and the death of the bacteria.
Clavulanic Acid Is known to reduce the resistance of bacteria. The combination of the salt present in tablets prevents bacteria from the roots and prevents infections primarily. Cefpodoxime and Clavulanic Acid Tablets are known to reduce bacterial infections, but only when accompanied by precautions.
Uses of Cefpodoxime and Clavulanic Acid Tablets
The tablets offer a coupled effect of two potent antibiotics. Cefpodoxime, which is a cephalosporin antibiotic, and Clavulanic Acid, which is known as the beta-lactamase inhibitor. They offer multiple beneficial uses; a few of them are given below as listed:
- This is a broad-spectrum antibiotic that prevents the growth of increased bacterial amounts in the body.
- It offers treatment for respiratory tract infections that can lead to severe tonsillitis and throat infections.
- The tablets also respond positively to community-acquired pneumonia.
- It is also preventive in reducing urinary tract infections and anorectal infections in women.
- The tablets also treat gonorrhea, a sexually transmitted disease.
The Cefpodoxime 200 mg and Clavulanic Acid 125 Mg Tablets are manufactured and offered for Franchise business; hence, these are profitable.
Here is the working mechanism of the composition.
The tablets form a protective layer on the cells, thereby preventing the attack of bacteria. These destroy the outer covering’s order layer of bacteria, leading to their death and reducing the other presence in the body by inhibiting the protein synthesis and the DNA development of bacteria.
Safety Measures and Precautions While Using Cefpodoxime and Clavulanic Acid Tablets
Precautions required with the use of this tablet are mentioned below.
- Take the tablets only after the recommendation of a doctor.
- If you are pregnant or you are breastfeeding, it is suggested that you not consume this antibiotic drug for the betterment of your own body.
- Consumption of alcohol and unhealthy food is strictly restricted.
- This is not recommended for pediatric use.
- Take the tablets in an orderly manner, specifically when you are under the influence of type 1 and type 2 diabetes.
- If you face liver infections or severe kidney damage, inform the doctor.
- If you are undergoing cancer treatment therapy, then do not use the drug if it cannot be ignored.
Side Effects of Cefpodoxime and Clavulanic Acid Tablets
The common side effects are,
- Nausea
- Drowsiness
- Vomiting
- Fatty liver
- Deficiencies
- Abdominal pain
How To Store Cefpodoxime and Clavulanic Acid Tablets
While storing these combination tablets, a few storage instructions are
- Store the tablets in a cool and dry place.
- Keep away from direct sunlight and moisture.
- Keep out of reach of children and pets.
- Do not use expired medication.
- Store them away from the sunlight.
Note – Cefpodoxime 200 mg and Clavulanic Acid 125 Mg Tablets are only for external use.
